Hypoxia-Inducible Factor-2 Alpha (HIF-2?) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
The Pharma Data
AUGUST 15, 2021
target genes associated with cellular proliferation, angiogenesis and tumor growth. Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. Advise patients of these risks and the need for effective non-hormonal contraception.
52 
Let's personalize your content